Although the clinical outcomes of diffuse large B-cell lymphoma (DLBCL) have improved in the immunochemotherapy era, approximately one-third of patients develop intractable disease. To improve clinical outcomes for these patients, it is important to identify those with poor prognosis prior to initial treatment in order to select optimal therapies. Here, we investigated the clinical and biological significance of SPIB, an Ets family transcription factor linked to lymphomagenesis, in DLBCL. We classified 134 DLBCL patients into SPIB negative (n = 108) or SPIB positive (n = 26) groups by immunohistochemical staining. SPIB positive patients had a significantly worse treatment response and poor prognosis compared with SPIB negative patients. Multivariate analysis for patient survival indicated that SPIB expression was an independent poor prognostic factor for both progression free survival (PFS) and overall survival (OS) (PFS, hazard ratio [HR] 2.65, 95% confidence interval [CI] 1.31-5.33, P = 0.006; OS, HR 3.56, 95% CI 1.43-8.91, P = 0.007). Subsequent analyses of the roles of SPIB expression in DLBCL pathogenesis revealed that SPIB expression in lymphoma cells resulted in resistance to the BH3-mimetic ABT-263 and contributed to apoptosis resistance via the PI3K-AKT pathway. The inhibition of AKT phosphorylation re-sensitized SPIB expressing lymphoma cells to ABT-263-induced cell death. Together, our data indicate that SPIB expression is a clinically novel poor prognostic factor in DLBCL that contributes to treatment resistance, at least in part, through an anti-apoptotic mechanism.
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T he clinical outcomes of diffuse large B-cell lymphoma (DLBCL) have improved in the rituximab era.
(1-3) However, the prognoses for intractable subtypes such as double hit lymphoma and EBV positive lymphoma remain unsatisfactory. (4) (5) (6) (7) To improve the clinical outcomes for patients diagnosed with these poor prognostic subtypes, it is essential to accurately stratify patients prior to initial treatment to facilitate the selection of optimal therapies.
SPIB, a member of the Ets family of transcription factors, is located on chromosome 19q, and plays an important role in the differentiation of mature B-cells into plasma cells, and the differentiation of plasmacytoid dendritic cells. (8) (9) (10) (11) (12) Activation of IRF4 is an initial event in the plasmacytic differentiation of mature B-cells, and leads to the upregulation of BLIMP1 and downregulation of BCL6. The upregulation of BLIMP1 induces the subsequent downregulation of SPIB, which is indispensable for normal differentiation. Therefore, the ectopic expression of SPIB during terminal B-cell differentiation results in inhibition of plasma cell differentiation and contributes to the development of the activated B-cell (ABC) type of DLBCL. (9, 13, 14) Moreover, the amplification of chromosome 19q, on which SPIB is located, is frequently detected in DLBCL and primary central nervous system lymphoma. (9, (15) (16) (17) A recent report also revealed that the expression of SPIB is elevated in BCL2 and MYC double positive lymphoma, (6) which suggests that SPIB overexpression might be associated with this poor prognostic phenotype.
Here, we investigated the clinical and biological significance of deregulated SPIB expression in DLBCL pathogenesis and identified SPIB as a novel molecular target in intractable DLBCL subtypes.
Materials and Methods
Patients. A total of 134 patients diagnosed with DLBCL at Nagoya University Hospital between 2006 and 2013 were analyzed in this study. The study protocol for the experimental use of pathological specimens and patient information was approved by the institutional review board of Nagoya University Hospital and complied with all provisions of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the Ministry of Health, Labour and Welfare in Japan.
Drugs and cell lines. The following drugs used in this study were purchased: ABT-263 (AdooQ BioScience, Irwin, CA, USA), LY294002 (Cayman Chemical Company, Ann Arbor, MI, USA), Ibrutinib and Idelalisib (Selleck Chemicals, Houston, TX, USA). 293T and SU-DHL4 (a kind gift from Dr Kunihiko Takeyama, Dana Farber Cancer Institute, Boston, MA, USA) cells were cultured in DMEM (Sigma Aldrich, St Louis, MO, USA) and RPMI (Sigma Aldrich), respectively. Both culture media were supplemented with 10% FCS, 2 mM L-glutamine, 100 U/mL penicillin, 100 lg/mL streptomycin and 1 mM sodium pyruvate.
Immunohistochemistry. Formalin fixed, paraffin embedded tissues were evaluated by routine HE and immunohistochemical staining (IHC). For IHC of CD20, BCL2, BCL6, CD10, MUM1, CD5 and MYC, the following primary antibodies were used: mouse monoclonal anti-human CD20 (clone L26) and BCL2 (clone 124) antibodies (Dako, Glostrup, Denmark), mouse monoclonal anti-human BCL6 (clone LN22), CD10 (clone 56C6) and CD5 (clone 4C7) antibodies (Novocastra, Leica Biosystems, Newcastle Upon Tyne, UK), M-17 antibody against MUM1 (sc-6059, Santa Cruz Biotechnology, Dallas, TX, USA), and rabbit monoclonal anti-human c-MYC antibody (clone Y69; Abcam, Cambridge, UK). EBV-encoded RNA expression was also routinely evaluated by in-situ hybridization (EBER-ISH). Anti-SPIB mouse monoclonal antibody (clone 4G5, ab135238; Abcam) was used as the primary antibody targeting SPIB. Immunohistochemical detection of SPIB was performed according to the following procedure. After deparaffinization and rehydration of the sections using a microwave oven, antigen retrieval was performed in low pH Target Retrieval Solution (Dako) for 20 min at 98°C. The sections were subsequently incubated with primary antibody at 4°C overnight followed by the addition of biotin-conjugated secondary antibody for 1 h at room temperature, and staining was activated by addition of the avidin-biotin complex (ABC). HRP activity was detected using 3, 3-diaminobenzidine tetrahydrochloride (DAB). All pathological specimens were reviewed by two hematopathologists (S.S. and S.N.) according to the current WHO classification. The specimens were observed with an Olympus BX51 N-34 microscope (Olympus, Tokyo, Japan), and the photos were taken with a Nikon DS-Fil1 (Nikon, Tokyo, Japan) and BZ-9000 (Keyence, Osaka, Japan).
SPIB expression vector and transfection/transduction procedures. To develop a SPIB expression vector, a FLAG tagged fragment of full length SPIB (FLAG-SPIB) was sub-cloned into the pCRII-TOPO plasmid (Invitrogen in Thermo Fisher Scientific, Waltham, MA, USA). Subsequently, the vector was digested with EcoRI and transferred to the retrovirus vector MIGR1 (a kind gift from Dr W. S. Pear, University of Pennsylvania, Philadelphia, PA, USA), which constitutively expresses GFP, to generate MIGR1-FLAG-SPIB. The DNA sequence of FLAG-SPIB cloned into MIGR1 was confirmed by sequence analysis. Transient transfection of the MIGR1 control vector (MOCK) and MIGR1-FLAG-SPIB into 293T cells was performed using the Effectene transfection reagent (Qiagen, Venlo, the Netherlands) according to the manufacturer's protocol. The stable transduction of SU-DHL4 cells using MIGR1 vectors was performed using a retroviral infection system (Retro-X Expression systems; Clontech in Takara Bio, Shiga, Japan). In brief, the MIGR1 vector and envelope vector (pVSV-G) were co-transfected into the GP2-293 packaging cell line using the FuGENE6 transfection reagent (Promega, Fitchburg, WI, USA). Two to 4 days later, retrovirus was harvested from the culture supernatant and applied to SU-DHL4 cell lines. SU-DHL4 cells transduced with MIGR1 vector were sorted for GFP expression using a FACSAria II (Becton-Dickinson [BD], Franklin Lakes, NJ, USA).
Cell proliferation assay. Cell proliferation was assessed by trypan blue-exclusion tests and MTT assays. Cells (2.0 9 10 4 SU-DHL4 cells) were placed in 96-well plates and cultured for 96 h at 37°C in a 5% CO 2 incubator. The number of live cells was counted every 24 h using trypan blue staining. For MTT assays, the same number of cells used for the trypan blue test (center panels) and SPIB (right panels) are shown. CD20 positive tumor cells diffusely proliferate in the lymph node. Specimens UPN#15 and UPN#72 were assessed as SPIB negative, while UPN#107, UPN#123 and UPN#145 were assessed as SPIB positive (original magnification 400 9 , Keyence BZ-9000). were placed in 96-well plates and cultured for 72 h. MTT labelling reagent (Roche Diagnostics, Mannheim, Germany) was then added to each well and incubated for 3 h. Fluorescence was evaluated at 490 nM with a GloMax Multi+ (Promega, Madison, WI, USA).
Cell cycle and cell death assessment. A hypotonic propidium iodide (PI) assay was used to evaluate the cell cycle, as described previously. (18) (19) (20) In brief, cells were incubated for 48 h with various drugs, washed, and re-suspended in PBS containing 0.2% Triton X-100 and 50 lg/mL PI. Subsequently, cells were analyzed by flow cytometry (FACSCalibur [BD]). For cell death assays, MIGR1-FLAG-SPIB transduced cells were incubated in 96-well plates with the appropriate drugs for 48 h. Cells were then stained with 5 lg/mL PI for 15 min in the dark and evaluated by flow cytometry.
Immunofluorescence staining. To evaluate SPIB expression in MIGR1-FLAG-SPIB transfected 293T and transduced SU-DHL4 cells, we performed immunofluorescence staining using the same anti-SPIB monoclonal antibody used for IHC. In brief, 293T cells were transfected with MIGR1-FLAG-SPIB using the Effectene Transfection Reagent according to the manufacturer's protocol (Qiagen) and placed in a chamber slide (Nunc in Thermo Fisher Scientific, Waltham, MA, USA). At 50-80% confluency, cells were fixed with 1:1 methanol/ acetone fixative at À20°C. Slides were subsequently dried and blocked in PBS containing 1% BSA. The slide was incubated with anti-SPIB primary antibody at 4°C overnight, and subsequently Alexa-568 conjugated anti-mouse IgG (H+L) secondary antibody for 1 h at room temperature; DAPI was then applied as a counterstain. SU-DHL4 cells were applied to slides using the cytospin method and then stained in a similar way. Specimens were viewed and photographed with an Axio Imager M2 (Carl Zeiss, Oberkochen, Germany).
Immunoblotting. Cells were treated with the various drugs and then lysed as described previously. (18, 21) To prevent postlysis changes in phosphorylation, 50 mM NaF and 1.68 mM Na 3 VO 4 were added. After centrifugation (11700 g for 10 min), the protein concentrations of lysates were evaluated by the Bradford method, and sample buffer containing 5% 2-mercaptoethanol was added. After boiling for 5 min, 20-lg samples were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes, and blocked with 5% skim milk in TBS-tween buffer (50 mM Tris-HCL [pH 7.4], 150 mM NaCl and 0.05% Tween 20) . Immunoblotting was performed using primary antibodies appropriately diluted in TBS-tween buffer containing 5% BSA and 0.05% sodium azide (Table S1 ). HRP conjugated secondary antibodies (GE Healthcare, Little Chalfont, UK) were added and activated with Immobilon Western Substrate (Millipore, Billerica, MA, USA). Images were obtained using a LAS 4000mini bio-imager (Fujifilm, Tokyo, Japan) and analyzed with MultiGauge software (Fujifilm).
Statistical analysis. The statistical significance of in vitro experiments was evaluated by an unpaired t-test using GraphPad PRISMv5 software (GraphPad Software, La Jolla, CA, USA). The distribution of clinical variables was evaluated by Fisher's exact test or Mann-Whitney U test. Treatment response was evaluated according to the revised response criteria. (22) Progression free survival (PFS) was calculated from the day of diagnosis to the day of progression, relapse or death. Overall survival (OS) was calculated from the day of diagnosis to the day of death by any cause. PFS and OS were analyzed with the log-rank test, and results were determined by the Kaplan-Meier method. Univariate and multivariate Cox regression analyses were performed to evaluate the following parameters: age, sex, performance status (PS), lactate dehydrogenase (LDH), clinical stage, extranodal involvement, B symptoms, DLBCL cell of origin determined by IHC, (23) leukocytosis, anemia and thrombocytopenia, in addition to the levels of sIL-2R, total protein, albumin, creatinine, serum urine acid, ALP, total bilirubin, C-reactive protein, IgG, IgA and IgM. Multivariate analyses for PFS and OS were undertaken using the forward-backward stepwise method. All probability values were two-sided, with an overall significance level of 0.05. All statistical analyses of clinical subjects were analyzed with Stata 10SE software (Stata Corp, College Station, TX, USA)
Results
Immunohistochemical staining of SPIB. Of 134 patients, 26 (19%) were assessed as SPIB positive, and the remaining 108 patients (81%) were SPIB negative. SPIB staining was scored positive only when it occurred in the cytoplasm and/or nucleus of lymphoma cells and not in the surrounding vascular Table 1 . In all patients, the proportions of patients in the SPIB positive group who had extranodal involvement, higher international prognostic index score (IPI) and MYC positivity in IHC were significantly greater than those in the SPIB negative group. There was a significantly higher proportion of patients who were BCL6 positive by IHC in the SPIB negative group. The incidence of double positive lymphoma (MYC and BCL2 co-expression by IHC) (7, 24) did not significantly differ between the two groups. Other clinical variables including age, sex and DLBCL cell of origin determined by IHC were not significantly different. Ninety-six (89%) and 25 patients (96%) in the SPIB negative and positive groups, respectively, received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) or R-CHOP-like regimens as initial treatment. In patients who were evaluable for initial treatment, 96 of 104 patients (92%) in the SPIB negative group and 15 of 24 patients (63%) in the SPIB positive group achieved a treatment response (complete response [CR] + partial response [PR]) (P = 0.001). CR rates were 86% in the SPIB negative group and 50% in the SPIB positive group (P < 0.001). The rate of progressive disease during the initial treatment in the SPIB positive group was 38%, which was significantly higher than that in the SPIB negative group (P = 0.001). We subsequently assigned all patients to one of two groups according to the cell of origin. Of the 132 patients for whom the cell of origin was evaluable by IHC, 47 (36%) and 85 (64%) patients were classified into GCB type DLBCL and non-GCB type DLBCL, respectively. Of the 47 patients, 12 (26%) with GCB type were assessed as SPIB positive, whereas 14 of the 85 patients (16%) with non-GCB type were assessed as SPIB positive. In patients with GCB type, the proportion of patients in the SPIB positive group that were MYC positive by IHC was significantly higher than that in the SPIB negative group, whereas the proportion of patients in the SPIB negative group that were positive for BCL6 expression by IHC was significantly higher than that in the SPIB positive group, which was similar to the case in the total DLBCL population. CR rates were 85% in the SPIB negative group and 25% in the SPIB positive group (P < 0.001). In patients with the non-GCB type, the proportions of patients with a higher IPI score and elevated sIL-2R in the SPIB positive group were greater than those in the SPIB negative group. However, the CR rate did not differ between the two groups.
With a median follow up of 39 months for surviving patients in all patients, PFS at 3 years was 38% in the SPIB positive group (95% confidence interval [CI], 18-58%) and 74% in the SPIB negative group (95% CI, 63-82%) (P < 0.001) (Fig. 2a) . OS at 3 years was 59% in the SPIB positive group (95% CI, 32-78%) and 79% in the SPIB negative group (95% CI, 69-86%) (P = 0.024) (Fig. 2b) . In patients with GCB type, PFS at 3 years was 17% in the SPIB positive group (95% confidence interval (CI), 1-48%) and 75% in the SPIB negative group (95% CI, 61-84%) with a median follow-up duration of 39 months for surviving patients (P < 0.001) (Fig. 2c ). OS at 3 years was 22% in the SPIB positive group (95% CI, 1-58%) and 85% in the SPIB negative group (95% CI, 68-94%) (P = 0.002) (Fig. 2d) . In patients with non-GCB type, PFS at 3 years was 56% in the SPIB positive group (95% confidence interval [CI], 23-79%) and 75% in the SPIB negative group (95% CI, 61-84%) with a median follow-up duration of 40 months for surviving patients (P = 0.201) (Fig. 2e ). OS at 3 years was 88% in the SPIB positive group (95% CI, 39-98%) and 77% in the SPIB negative group (95% CI, 64-86%) (P = 0.682) (Fig. 2f) . Overall, the outcomes for PFS of patients with non-GCB type DLBCL were significantly better than those with GCB type DLBCL (P = 0.013; Fig. S1 ) Prognostic factors. Prognostic factors for patient survival were evaluated by the Cox proportional hazard model. The univariate analyses for PFS and OS for all patients, and for patients with GCB type and non-GCB type, are shown in Tables S2-S4, respectively. In all patients, multivariate analyses of prognostic factors revealed that SPIB positivity was an independent poor prognostic factor for PFS (HR 2.65, 95% CI 1.31-5.33, P = 0.006) and for OS (HR 3.56, 95% CI 1.43-8.91, P = 0.007). Intriguingly, male sex was a poor prognostic factor for both PFS and OS (PFS, HR 3.55, 95% CI 1.58-8.02, P = 0.002; OS, HR 10.5, 95% CI 2.36-46.2, P = 0.002). In patients with GCB type, SPIB was also an independent poor prognostic factor for PFS (HR 4.50, 95% CI 1.39-14.6, P = 0.012) and for OS (HR 18.9, 95% CI 3.59-99.5, P = 0.001). In contrast, SPIB was not identified as a poor prognostic factor in patients with non-GCB type. Male sex was a poor prognostic factor for PFS and OS of non-GCB type (PFS, HR 4.60, 95% CI 1.33-15.9, P = 0.016; OS, HR 10.2, 95% CI 1.31-78.8, P = 0.027) ( Table 2) .
Development of an SPIB expression vector. The analysis of clinical outcomes suggested that SPIB expression was a poor prognostic factor in DLBCL, especially in GCB-type DLBCL. To address this possibility in more detail and evaluate the biological significance of SPIB expression in DLBCL, we developed a retroviral SPIB expression vector, MIGR1-FLAG-SPIB (Fig. 3a) . We confirmed the expression of Flagtagged SPIB by immunoblotting after transient transfection of 293T cells (Fig. 3b(i) ). Next, we used the MIGR1-FLAG-SPIB retrovirus to transduce the SU-DHL4 cell line, which has a relatively low endogenous expression of SPIB mRNA. Cells constitutively expressing GFP were purified by cell sorting, and the expression of Flag-tagged SPIB was confirmed by immunoblotting (Fig. 3b(ii) ). To confirm that the SPIB antibody used for IHC staining recognized SPIB, we assessed the immunofluorescence (IF) of MIGR1-FLAG-SPIB transfected 293T cells and retrovirally transduced SU-DHL4 cells. As shown in Figure 3 (Fig. 4a) . The cell cycle was not significantly different between the wild type (WT), MOCK and FLAG-SPIB-DHL4 cell lines (Fig. 4b) . on susceptibilities to the standard anti-cancer drugs used in the clinic. First, we analyzed the susceptibility of FLAG-SPIB-DHL4 cells to the chemotherapeutic drugs used in CHOP therapy, and found that these drugs killed the MOCK and FLAG-SPIB-DHL4 cells with equal efficiency (data not shown). Next, we evaluated their susceptibilities to molecular targeted drugs. In the presence of the BH3 mimetic, ABT-263, the FLAG-SPIB-DHL4 cell line was more resistant to ABT-263 mediated cell death than the MOCK cell line (Fig. 4c) . The concentration of ABT-263 required for 50% growth inhibition (GI 50 ) in the FLAG-SPIB-DHL4 cell line (3.73 lM) was significantly higher than that required for the MOCK cell line (0.50 lM) (P = 0.015) (Fig. 4d) . Subsequently, we analyzed the expression of various apoptotic proteins in the WT, MOCK and FLAG-SPIB-DHL4 cell lines in the presence or absence of ABT-263. Compared to MOCK cells, in FLAG-SPIB-DHL4 cells treated with ABT-263, the induction of cleaved caspase 3 was suppressed, and the expression of the anti-apoptotic protein, MCL1, was maintained, which indicated that forced SPIB expression had an anti-apoptotic effect (Fig. 4e) . The expression of BCL-xL, an ABT-263 target, was similar to that of MCL1, while the expression of another ABT-263 target, BCL2, did not differ among the WT, MOCK and FLAG-SPIB-DHL4 cell lines irrespective of the presence or absence of ABT-263 (Fig. S2) . In concert with the maintenance of MCL1 expression in the presence of ABT-263 in FLAG-SPIB-DHL4 cells, the induction of pro-apoptotic NOXA expression was suppressed. Next we analyzed the AKT and ERK cell survival pathways upstream of MCL1 and found that the expression of phosphorylated AKT (pAKT) was retained in FLAG-SPIB-DHL4 cells, consistent with AKT pathway activation. Subsequently, we also analyzed the expression of the pro-apoptotic BAD protein that acts downstream from AKT. As anticipated, expression of phosphorylated BAD Caspase-3 and GAPDH as a loading control were analyzed. All of the images except those of pERK1/ 2 and ERK1/2 were derived from the same membrane. The pERK1/2 and ERK1/2 images were taken from a separate membrane using the same cell lysate. (pBAD) was retained in the FLAG-SPIB-DHL4 cell line. Moreover, the expression of the anti-apoptotic protein, BFL1, was induced in the FLAG-SPIB-DHL4 cell line (Fig. 4e) . These combined data indicated that SPIB expression had an anti-apoptotic effect and acted via the AKT pathway.
Overcoming resistance to apoptosis through the inhibition of AKT phosphorylation. As SPIB expression is involved in antiapoptosis via the AKT pathway, we investigated whether SPIB induced anti-apoptosis could be overcome through the inhibition of pAKT in the FLAG-SPIB-DHL4 cell line. In the presence of 5 lM ibrutinib, 25 lM idelalisib and 10 lM LY294002 without ABT-263, limited cell death was observed. However, when these drugs at the same dosages were combined with >0.2 lM ABT-263, cell death was clearly increased (Fig. 5a ). In the reverse experiment, various doses of ibrutinib, idelalisib and LY294002 combined with 0.2 lM ABT-263 increased cell death compared with cells treated with ibrutinib, idelalisib and LY294002 individually (Fig. 5b) . To confirm that these combination effects were specifically associated with the inhibition of AKT, we investigated the phosphorylation status of AKT by immunoblotting in the presence or absence of ABT-263 and ibrutinib, idelalisib and LY294002. As expected, phosphorylation of AKT and ERK decreased in the presence of high doses of ibrutinib, idelalisib and LY294002 individually or combined with ABT-263. Consistent with the cell death induced by the combination of AKT inhibitors and ABT-263, MCL1 was degraded in concert with the induction of NOXA expression and decreased expression of pBAD (Fig. 5c ). Taken together these data indicate that inhibition of pAKT and pERK, upstream of MCL1, re-sensitizes FLAG-SPIB-DHL4 cells to ABT-263-induced apoptosis. This effect also indicates that AKT is a potential therapeutic target in SPIB high expressing lymphoma cells.
Discussion
In this analysis, we evaluated SPIB expression in DLBCL by routine immunohistochemical staining and demonstrated that SPIB expression was a novel poor prognostic factor and potential biomarker for DLBCL that is, at least in part, involved in apoptosis resistance via the PI3K-AKT pathway. We focused on 134 patients with DLBCL in a single institute. Overall, male sex, poor PS, elevated LDH, elevated IgG and SPIB expression were independent poor prognostic factors for OS, and male sex, poor PS, GCB type DLBCL, MYC/ BCL2 co-expression, SPIB expression and elevated sIL-2R were poor prognostic factors for PFS. The fact that poor PS and MYC/BCL2 co-expression were poor prognostic factors for survival is consistent with other studies. (24, 25) However, the finding that male sex was the strongest poor prognostic factor for OS in all patients and in patients with non-GCB type was unexpected and may reflect the potential difference in therapeutic efficacy of rituximab in men and women, (26, 27) another as yet unidentified sex-specific susceptibility factor, or a cohort-specific statistical anomaly. These possibilities should be prospectively addressed in larger cohorts.
We detected SPIB expression by IHC in 19% of all patients, 26% of patients with GCB type and 16% of non-GCB type, which is consistent with a previous report of chromosome 19q amplification in 15% of DLBCL patients. (9) Moreover, patients with SPIB expression in all patients and in GCB type demonstrated poorer outcomes, whereas SPIB expression was not associated with poorer prognoses in patients with non-GCB type, possibly due to the better outcomes of non-GCB type DLBCL. In accordance with previous findings regarding the role of SPIB expression in lymphomagenesis in ABC type DLBCL, the present findings regarding the association of SPIB expression with clinical presentations and its anti-apoptotic effect in GCB type DLBCL suggest that SPIB expression is linked to pathogenesis in both GCB and ABC type DLBCL. Intriguingly, a recent finding indicated that SPIB expression was associated with MYC/BCL2 double positive lymphoma, (6) which is considered to be a poor prognostic phenotype; (7, 24) however, SPIB was not linked to MYC/BCL2 co-expression in our multivariate analysis. These combined findings might suggest that SPIB expression is linked to a poor prognostic phenotype through its anti-apoptotic effect in GCB type DLBCL and to lymphomagenesis through the inhibition of plasma cell differentiation in ABC type DLBCL (Fig. 5d) . Although we uncovered some aspects of the role of SPIB expression in DLBCL pathogenesis, SPIB may be involved in other processes linked to patient survival. Further investigation is warranted.
Forced expression of SPIB in tumor cells produced an antiapoptotic effect linked to the AKT-BAD axis and MCL1 expression. Moreover, the inhibition of AKT phosphorylation overcame apoptosis resistance. These findings highlight a novel function of SPIB in the regulation of the AKT pathway. Considering that inhibition of AKT pathway signaling is an attractive molecular target, SPIB expression could be a useful surrogate marker for future combination therapy.
Although our data suggest that SPIB is a novel prognostic factor in DLBCL and the SPIB linked anti-apoptotic effect might be a potential mechanism underlying the poor prognostic phenotype, it is important to acknowledge the limitations of our study. First, our cohort was derived from a single institute in a retrospective manner, raising the possibility that institutional and/or unrecognized bias might lead to an overestimation of the role of SPIB expression in DLBCL pathogenesis. Second, we did not detect resistance to anti-chemotherapy drugs other than ABT-263 in FLAG-SPIB-DHL4 cells. Nevertheless, our data contribute significantly to uncovering the role (s) of SPIB in DLBCL pathogenesis, including, importantly, an anti-apoptotic function acting via the PI3K-AKT pathway.
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